vs
Journey Medical Corp（DERM）与Research Solutions, Inc.（RSSS）财务数据对比。点击上方公司名可切换其他公司
Journey Medical Corp的季度营收约是Research Solutions, Inc.的1.4倍（$16.1M vs $11.8M），Research Solutions, Inc.净利率更高（4.6% vs -7.8%，领先12.4%），Journey Medical Corp同比增速更快（27.3% vs -1.0%），过去两年Journey Medical Corp的营收复合增速更高（11.0% vs -1.3%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
雅各布斯解决方案是一家总部位于美国达拉斯的国际技术专业服务企业，面向全球各类客户（包括企业、机构及政府部门）提供工程、技术、专业、建筑相关服务，以及科研与专项咨询服务，常年位居《工程新闻纪录》顶级设计企业榜单榜首。
DERM vs RSSS — 直观对比
营收规模更大
DERM
是对方的1.4倍
$11.8M
营收增速更快
DERM
高出28.3%
-1.0%
净利率更高
RSSS
高出12.4%
-7.8%
两年增速更快
DERM
近两年复合增速
-1.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $11.8M |
| 净利润 | $-1.2M | $546.9K |
| 毛利率 | — | 52.4% |
| 营业利润率 | -2.8% | 6.3% |
| 净利率 | -7.8% | 4.6% |
| 营收同比 | 27.3% | -1.0% |
| 净利润同比 | -182.0% | 127.6% |
| 每股收益（稀释后） | $-0.04 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMRSSS
| Q4 25 | $16.1M | $11.8M | ||
| Q3 25 | $17.0M | $12.3M | ||
| Q2 25 | $15.0M | $12.4M | ||
| Q1 25 | $13.1M | $12.7M | ||
| Q4 24 | $12.6M | $11.9M | ||
| Q3 24 | $14.6M | $12.0M | ||
| Q2 24 | $14.9M | $12.1M | ||
| Q1 24 | $13.0M | $12.1M |
净利润DERMRSSS
| Q4 25 | $-1.2M | $546.9K | ||
| Q3 25 | $-2.3M | $749.4K | ||
| Q2 25 | $-3.8M | $2.4M | ||
| Q1 25 | $-4.1M | $216.5K | ||
| Q4 24 | $1.5M | $-2.0M | ||
| Q3 24 | $-2.4M | $669.0K | ||
| Q2 24 | $-3.4M | $-2.8M | ||
| Q1 24 | $-10.4M | $76.3K |
毛利率DERMRSSS
| Q4 25 | — | 52.4% | ||
| Q3 25 | — | 50.6% | ||
| Q2 25 | — | 51.0% | ||
| Q1 25 | — | 49.5% | ||
| Q4 24 | 82.3% | 48.9% | ||
| Q3 24 | 63.9% | 47.9% | ||
| Q2 24 | 56.0% | 46.5% | ||
| Q1 24 | 47.7% | 45.2% |
营业利润率DERMRSSS
| Q4 25 | -2.8% | 6.3% | ||
| Q3 25 | -9.0% | 7.8% | ||
| Q2 25 | -19.2% | 9.7% | ||
| Q1 25 | -25.3% | 4.4% | ||
| Q4 24 | 17.7% | 0.8% | ||
| Q3 24 | -19.8% | 5.4% | ||
| Q2 24 | -19.7% | 5.5% | ||
| Q1 24 | -77.4% | 0.7% |
净利率DERMRSSS
| Q4 25 | -7.8% | 4.6% | ||
| Q3 25 | -13.6% | 6.1% | ||
| Q2 25 | -25.3% | 19.0% | ||
| Q1 25 | -31.0% | 1.7% | ||
| Q4 24 | 12.1% | -16.6% | ||
| Q3 24 | -16.3% | 5.6% | ||
| Q2 24 | -22.6% | -23.3% | ||
| Q1 24 | -80.1% | 0.6% |
每股收益（稀释后）DERMRSSS
| Q4 25 | $-0.04 | $0.02 | ||
| Q3 25 | $-0.09 | $0.02 | ||
| Q2 25 | $-0.16 | $0.08 | ||
| Q1 25 | $-0.18 | $0.01 | ||
| Q4 24 | $0.10 | $-0.07 | ||
| Q3 24 | $-0.12 | $0.02 | ||
| Q2 24 | $-0.17 | $-0.09 | ||
| Q1 24 | $-0.53 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | $12.3M |
| 总债务越低越好 | $25.3M | — |
| 股东权益账面价值 | $31.9M | $17.2M |
| 总资产 | $94.6M | $44.2M |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资DERMRSSS
| Q4 25 | $24.1M | $12.3M | ||
| Q3 25 | $24.9M | $12.0M | ||
| Q2 25 | $20.3M | $12.2M | ||
| Q1 25 | $21.1M | $9.9M | ||
| Q4 24 | $20.3M | $7.7M | ||
| Q3 24 | $22.5M | $6.9M | ||
| Q2 24 | $23.9M | $6.1M | ||
| Q1 24 | $24.1M | $4.2M |
总债务DERMRSSS
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
股东权益DERMRSSS
| Q4 25 | $31.9M | $17.2M | ||
| Q3 25 | $25.9M | $15.6M | ||
| Q2 25 | $19.2M | $13.9M | ||
| Q1 25 | $21.5M | $11.2M | ||
| Q4 24 | $20.1M | $11.1M | ||
| Q3 24 | $10.9M | $12.8M | ||
| Q2 24 | $11.3M | $11.7M | ||
| Q1 24 | $13.0M | $14.1M |
总资产DERMRSSS
| Q4 25 | $94.6M | $44.2M | ||
| Q3 25 | $85.2M | $45.5M | ||
| Q2 25 | $81.2M | $46.1M | ||
| Q1 25 | $85.0M | $45.2M | ||
| Q4 24 | $80.2M | $42.8M | ||
| Q3 24 | $64.0M | $41.4M | ||
| Q2 24 | $65.2M | $41.9M | ||
| Q1 24 | $66.6M | $40.8M |
负债/权益比DERMRSSS
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | $1.4M |
| 自由现金流经营现金流 - 资本支出 | — | $1.4M |
| 自由现金流率自由现金流/营收 | — | 11.7% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | — | 2.53× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DERMRSSS
| Q4 25 | $-6.3M | $1.4M | ||
| Q3 25 | $-2.4M | $1.1M | ||
| Q2 25 | $-942.0K | $2.3M | ||
| Q1 25 | $-2.8M | $2.9M | ||
| Q4 24 | $2.2M | $1.0M | ||
| Q3 24 | $-1.2M | $843.1K | ||
| Q2 24 | $-5.2M | $2.0M | ||
| Q1 24 | $-5.0M | $2.0M |
自由现金流DERMRSSS
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $2.0M |
自由现金流率DERMRSSS
| Q4 25 | — | 11.7% | ||
| Q3 25 | — | 8.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 22.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 16.0% | ||
| Q1 24 | — | 16.6% |
资本支出强度DERMRSSS
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.0% |
现金转化率DERMRSSS
| Q4 25 | — | 2.53× | ||
| Q3 25 | — | 1.48× | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | 13.36× | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 26.43× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
RSSS
| Transactions | $6.6M | 56% |
| Platforms | $5.2M | 44% |
